From the Editor

In which clinical situations can the use of the 52-mg levonorgestrel-releasing IUD (Mirena) and the TCu380A copper-IUD (ParaGard) be extended?

OBG Manag. 2016 September;28(9):8, 9, 13, 16

PDF Download

References

Mirena [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; July 2008. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021225s019lbl.pdf. Accessed July 28, 2016.
ParaGard [package insert]. N. Tonawanda, NY: FEI Women’s Health LLC; revised September 2005. http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018680s060lbl.pdf. Accessed July 28, 2016.
Liletta [package insert]. Parsippany, NJ: Actavis Pharma, Inc; February 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206229s000lbl.pdf. Accessed July 28, 2016.
Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the copper T380 Ag IUDS. Contraception. 1991;44(5):473–480.
Díaz J, Faúndes A, Díaz M, Marchi N. Evaluation of the clinical performance of a levonorgestrel-releasing IUD, up to seven years of use, in Campinas, Brazil. Contraception. 1993;47(2):169–175.
Rönnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand. 1999;78(8):716–721.
Hidalgo MM, Hidalgo-Regina C, Bahamondes MV, Monteiro I, Petta CA, Bahamondes L. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. Contraception. 2009;80(1):84–89.
McNicholas C, Maddipati R, Zhao Q, Swor E, Peipert JF. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration. Obstet Gynecol. 2015;125(3):599–604.
Rowe P, Farley T, Peregoudov A, et al. Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A. Contraception. 2016;93(6):498–506.
Wu JP, Pickle S. Extended use of the intrauterine device: a literature review and recommendations for clinical practice. Contraception. 2014;89(6):495–503.
Bahamondes L, Faundes A, Sobreira-Lima B, Liu-Filho JF, Pecci P, Matera S. TCu 380A IUD: a reversible permanent contraceptive method in women over 35 years of age. Contraception. 2005;72(5):337–341.
United Nations Development Programme. Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception. 1997;56(6):341–352.
Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. Contraception. 2007;75(6 suppl):S70–S75.

References

Mirena [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; July 2008. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021225s019lbl.pdf. Accessed July 28, 2016.
ParaGard [package insert]. N. Tonawanda, NY: FEI Women’s Health LLC; revised September 2005. http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018680s060lbl.pdf. Accessed July 28, 2016.
Liletta [package insert]. Parsippany, NJ: Actavis Pharma, Inc; February 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206229s000lbl.pdf. Accessed July 28, 2016.
Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the copper T380 Ag IUDS. Contraception. 1991;44(5):473–480.
Díaz J, Faúndes A, Díaz M, Marchi N. Evaluation of the clinical performance of a levonorgestrel-releasing IUD, up to seven years of use, in Campinas, Brazil. Contraception. 1993;47(2):169–175.
Rönnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand. 1999;78(8):716–721.
Hidalgo MM, Hidalgo-Regina C, Bahamondes MV, Monteiro I, Petta CA, Bahamondes L. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. Contraception. 2009;80(1):84–89.
McNicholas C, Maddipati R, Zhao Q, Swor E, Peipert JF. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration. Obstet Gynecol. 2015;125(3):599–604.
Rowe P, Farley T, Peregoudov A, et al. Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A. Contraception. 2016;93(6):498–506.
Wu JP, Pickle S. Extended use of the intrauterine device: a literature review and recommendations for clinical practice. Contraception. 2014;89(6):495–503.
Bahamondes L, Faundes A, Sobreira-Lima B, Liu-Filho JF, Pecci P, Matera S. TCu 380A IUD: a reversible permanent contraceptive method in women over 35 years of age. Contraception. 2005;72(5):337–341.
United Nations Development Programme. Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception. 1997;56(6):341–352.
Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. Contraception. 2007;75(6 suppl):S70–S75.

In which clinical situations can the use of the 52-mg levonorgestrel-releasing IUD (Mirena) and the TCu380A copper-IUD (ParaGard) be extended?

References

Emergency contraception with immediate placement of an IUD

ParaGard and Mirena: Two highly effective contraceptives

Pages

Recommended Reading